Go To Main content
Unit_Image
:::

::: Adjunct Faculty

歐建志 Adjunct Faculty

歐建志 Adjunct Faculty      
Chien-Chih (Lance) Ou, Ph.D.

Position

Adjunct Assistant Professor, Graduate Institute and Department of Pharmacology, National Defense Medical University, Taipei, Taiwan

Contact

Mobile No.: +886-932-789-257
Email: lancelot.ou@gmail.com

Experience

1.Oct 2015 ~ Present
OBI Pharma:Present Associate Medical and Clinical Director
•Draft and Review the protocol
•Lead PM team to delivery assigned programs including Phase I/II trial design, initiation, conduction and monitoring in Oncology disease and healthy subjects (2 in preclinical, 5 in Phase I, 1 in Phase II, Deputy in Phase III)
•Bridging medical sciences from pre-clinical to Phase 1 (Translational Medicine)
•Identifie and assesse program risks; creates, implements and assesses effectiveness of mitigation plans
•Lead development of Safety Plan and adherence to ICH-GCP
•In collaboration with Regulatory colleagues contributes to clinical preparation for and attends meetings with regulatory agencies and the resolution of clinical queries from drug regulatory agencies
•Ensure appropriate medical and scientific expertise is consistently brought to all clinical program strategy, design, and execution and interpretation activities
•Maintains disease area knowledge relevant to the program, in particular with regards to design and outcome of clinical trials for competitors
•Maintains a productive, collaborative relationship with internal and external stakeholders/KOLs
•Oversee CROs and the project teams to deliver projects on time, on budget
•Assist BD to out-license
2.Jan 2011 ~ Sep 2015 SynCore and Sinphar Group:Senior Clinical Manager/Project & Medical Lead
•Lead and deliver clinical projects in Oncology (NCE) and botanical drug development including Phase I-III trial design, initiation, conduction, monitoring and close out
•Draft synopsis and review protocol
•Oversee CROs and the project teams to deliver projects on time, on budget and compliant with ICH GCP
•Responsible for Project and Budget Planning, Protocol drafting, Biomarker and Vendor searching and finalization
•Oversee CMC team to ensure quality of investigational products
•Responsible for operational excellence and timely production and approval of quality clinical deliverables for their program, such as Protocol development
•Strategically planning in Patent extension and filling
•KOLs and stakeholders Management
•Cooperate with BD team in In/Out licensing strategies
3.Jan 2008 ~ Dec 2010 Postdoctoral Study in Tri-Services General Hospital
•Lead labmates to study the interaction between Traditional Chinese Medicine and Stem Cells/Cancer Stem Cells
•Grant Application
•Papers drafting and submission
4.Jul 2009 ~now Adjunct Assistant Professor in National Defense Medical Center
•Teaching Pharmacology/Immune Oncology courses
5.Jan 2004 ~Dec 2008 Clinical Pharmacist in Keelung Hospital
6.Aug 1997 ~Aug 2000 Roche Pharmaceutical Company:Medical Sales Representative
•Neurologic/Psychiatric/Antibiotic/Anti-inflammatory drug sales as well as client training
7.Oct 1995 ~ Jun 1997 Military Doctor:Responsible for Administrative and Clinical Affairs

EDUCATION

Jan 2008 National Defense Medical College PhD Degree in Graduate School of
Medical Sciences (Major in Cancer Gene Therapy)
Aug 2002 National Defense Medical College Master Degree in Graduate School of Pharmacology (Clinical Pharmacology)
Aug 1995 Kaohsiung Medical University Bachelor Degree in Pharmacy

SKILLS & EXPERTISE

Oncology Drug Development (Trained in Medigene AG, Munich)
Early Phase Drug Development (Trained in Medigene AG, Munich)
Stem Cells & Cancer Stem Cells
Physiology & Pharmacology
Cancer Gene & Target Therapy
Sales and Marketing Strategies

LANGUAGE SKILLS:

Mandarin
English
Good communicator with team members

Publications

1. Chien-Chih Ou, Shih-Chung Hsu, Yin-Hui Hsieh, Wan-Ling Tzou, Tzu-Chao Chuang, Jah-Yao Liu, and Ming-Ching Kao (2008) Down-regulation of HER2 by RIG1 Involves the PI3K/Akt Pathway in Ovarian Cancer Cells. Carcinogenesis 29: 299-306 (IF=5.406, PhD dissertation)

2. Shih-Chung Hsu, Chien-Chih Ou, Tzu-Chao Chuang, Jhy-Wei Li, Han-Pon Kuo, Jah-Yao Liu, Chin-Shiang Chen, Song-Chow Lin and Ming-Ching Kao. (2008) Growth inhibition of colorectal cancer cells by Ganoderma tsugae extracts via G2/M cell cycle arrest. Journal of Enthopharmacology 120: 394-401

3. Shih-Chung Hsu, Chien-Chih Ou, Tzu-Chao Chuang, Jhy-Wei Li, Yi-Jen Lee, Vinchi Wang , Jah-Yao Liu, Chin-Shiang Chen, Song-Chow Lin, Ming-Ching Kao. (2009) Ganoderma tsugae extract Inhibits Expression of Epidermal Growth Factor Receptor and Angiogenesis in human epidermoid carcinoma Cells: in vitro and in vivo. Cancer Letters 281: 108-116

4. Chuang TC, Hsu SC, Cheng YT, Shao WS, Wu K, Fang GS, Ou CC, Wang V. (2011) Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells. Cancer Letters 311:11-19. (IF: 4.238)

5. Tsai YT, Liu JY, Lee CY, Tsai CS, Chen MH, Ou CC, Chen WH, Loh SH. (2011) Functional characterization of transmembrane intracellular pH regulators and mechanism of alcohol-induced intracellular acidosis in human umbilical cord blood stem cell-like cells. J Cardiovasc Pharmacol. 58:589-601.

6. Ou CC, Chen YW, Hsu SC, Sytwu HK, Loh SH, Li JW, Liu JY. (2012) Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB. Evid Based Complement Alternat Med. 2012:350239 (First author; IF: 4.774, Ranking No. 1)

7. Kuo HP, Hsu SC, Ou CC, Li JW, Tseng HH, Chuang TC, Liu JY, Chen SJ, Su MH, Cheng YC, Chou WY and Kao MC. (2013) Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med. 2013: 219472

8. 歐建志, 潘信保, 龍美雲. (2011) Stem Cells (淺談幹細胞). THE JOURNAL OF TAIWAN PHARMACY 27:116-120.

9. 潘信保, 龍美雲, 歐建志. (2012) Cancers & Cancer Stem Cells (癌症與癌症幹細胞). THE JOURNAL OF TAIWAN PHARMACY 28:74-77.

10. Lee YJ, Wu CC, Li JW, Ou CC, Hsu SC, Tseng HH, Kao MC, Liu JY. (2016) A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. Oncotarget 7: 78499–78515
11. Hsiu-Hsueh Tseng, Wan-Chun Yeh, Yun-Chen Tu, Bi-Fen Yang, Yen-Ting Lai, Yi-Jen Lee, Chien-Chih Ou, Han-Peng Kuo, Ming-Ching Kao, and Jah-Yao Liu. Proteomic profiling of Ganoderma tsugae ethanol extract-induced adipogenesis displaying browning features.. FEBS Letters. 2018 Apr 23. doi: 10.1002/1873-3468.13061. [Epub ahead of print]
SYMPOSIUM PAPERS (abstract and poster)
1. Cheng-I Lin, Chien-Chih Ou, Yi-Jen Chen, Yao-Chang Chen and Shih-Ann Chen (Jul, 2002) Electrophysiology and Arrhythmogenic Activity of Dog Left Inferior Pulmonary Veins, International Journal of Bioelectromagnetism, Montreal, Canada

2. Chien-Chih Ou, Shih-Chung Hsu, Yin-Hui Hsieh, Wan-Ling Tzou, Jah-Yao Liu, and Ming-Ching Kao (Apr, 2007) Down-regulation of HER2 by Interferon-γ-Induced RIG1 Followed by PI3K/Akt/mTOR/VEGF pathway in Ovarian Cancer Cells. American Association of Cancer Research (AACR), 2007 Annual Meeting, LA, USA

3. Chien-Chih Ou, Shih-Chung Hsu, Yin-Hui Hsieh, Wan-Ling Tzou, Jah-Yao Liu, and Ming-Ching Kao (Nov, 2007) Down-regulation of HER2 by RIG1 in Ovarian Cancer Cells. The 1st International Cancer Symposium, Nov 16-17, China Medical University, Taichung

4. Chien-Chih Ou, Yi-Jen Lee, Shih-Wei Tung and Jah-Yao Liu (Nov, 2008) Four-Agents-Decoction Suppresses HER2 Expression in Endometriosis. Annual Meeting of American Congress of Obstetricians and Gynecologists, CA, USA

5. Chien-Chih Ou, Shih-Chung Hsu, Yin-Hui Hsieh, Wan-Ling Tzou, Tzu-Chao Chuang, Jah-Yao Liu and Ming-Ching Kao (Nov, 2008) Downregulation of HER2 by RIG1 Involves the PI3K/Akt Pathway in Ovarian Cancer Cells. The 35th Conference of Military Doctors, Taipei

6. Chien-Chih Ou, Yi-Jen Lee and Jah-Yao Liu (Feb, 2009) Studying on the molecular mechanisms of Four-Agents-Decoction on dysmenorrheal. Annual Meeting of Taiwan Association of Obstetrics and Gynecology, Taichung

7. Chien-Chih Ou, Jah-Yao Liu, Ming-Ching Kao (May, 2009) Molecular Mechanisms of RIG1 Repressing HER2 and Its Downstream Pathway. The 13th Taiwan Joint Cancer Conference, Taipei

8. Chien-Chih Ou, Yuan-Wu Chen, Shih-Chung Hsu, Jah-Yao Liu (Nov, 2009) Downregulation of HER2 by Triptolide
Involves PI3K/Akt Pathway in Ovarian Cancer Cells. The 36th Conference of Military Doctors, Taipei

9. Chien-Chih Ou, Yi-Jen Lee, Shih-Chung Hsu, and Jah-Yao Liu (Nov, 2009) Four-Agents-Decoction Suppresses COX-2 Expression in Endometrial Cells: Possible Role in Relieving Dysmenorrhea. The 36th Conference of Military Doctors, Taipei

10 Han-Peng Kuo, Shih-Chung Hsu, Chien-Chih Ou, Jhy-Wei Li, Hsiu-Hsueh Tseng, Tzu-Chao Chuang, Jah-Yao Liu, Shih-Jung Chen, Muh-Hwan Su, Yung-Chi Cheng, Wei-Yuan Chou, and Ming-Ching Kao (Mar, 2013) Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway. 2013生物醫學年會, Taipei.

BOOKS

Pharmacology and the Nursing Process. (August 2004) Tsang-Hai Book Publishing Company.

AWARDS and HONORS

First Award poster in The 35th Joint Conference of Military Doctors.
Outstanding poster in The 36th Joint Conference of Military Doctors.
First Award poster in The 37th Joint Conference of Military Doctors.
Selected poster in The 13th Taiwan Joint Cancer Conference.
2018 NDMC Outstanding and Honorable Alumni Award

PATENTS

The efficacy study of SBM2 on the disruption of tumor vasculature (USPTO). Inventor: Chien-Chih Ou, Mel Su, Angeline Liu (Issued No: I594982)

    Views:165
  • Update Date:2026-03-05